Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6636176 | 0.84 | OPRM1 (0.61) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 | |
| SCHEMBL4630573 | 0.82 | OPRM1 (0.63) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 | |
| SCHEMBL16915778 | 0.81 | OPRM1 (0.58) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 | |
| SCHEMBL9231786 | 0.81 | OPRM1 (0.61) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 | |
| SCHEMBL989783 | 0.81 | OPRM1 (0.61) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 | |
| SCHEMBL14902471 | 0.79 | OPRM1 (0.60) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 | |
| SCHEMBL30328950 | 0.78 | OPRM1 (0.55) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 | |
| SCHEMBL24712978 | 0.77 | OPRM1 (0.65) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 | |
| SCHEMBL15461526 | 0.77 | CYP2D6 (0.59) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 | |
| SCHEMBL12022949 | 0.77 | OPRM1 (0.69) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112625028-B | Compounds and compositions for inhibiting SHP2 activity | 诺华股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-112625028-A | Compounds and compositions for inhibiting SHP2 activity | 诺华股份有限公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-107922388-B | Compounds and compositions for inhibiting SHP2 activity | 诺华股份有限公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-107787323-B | Compounds and compositions for inhibiting SHP2 activity | 诺华股份有限公司 | 2020-09-01 | — | — | CN | disclosed |
| EP-3310771-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2020-07-22 | — | — | EP | disclosed |
| EP-3310774-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2020-04-29 | — | — | EP | disclosed |
| US-10308660-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2019-06-04 | — | — | US | disclosed |
| US-10287266-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2019-05-14 | — | — | US | disclosed |
| US-20180251471-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-09-06 | — | — | US | disclosed |
| US-20180186770-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-07-05 | — | — | US | disclosed |
| EP-3310774-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | Novartis AG (CH) | 2018-04-25 | — | — | EP | disclosed |
| EP-3310771-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | Novartis AG (CH) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016203406-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016203405-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251471-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN3, PTPN1, PTPN2 | OPRM1 3849/4885CYP3A4 3488/4885HSD17B10 3560/4885 |
| US-20180186770-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN2 | OPRM1 4055/4885CYP3A4 4085/4885HSD17B10 3774/4885 |
| US-10308660-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN3, PTPN1, PTPN2 | OPRM1 3849/4885CYP3A4 3488/4885HSD17B10 3560/4885 |
| US-10287266-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN1, PTPN3, PTPN2 | OPRM1 4125/4885CYP3A4 3991/4885HSD17B10 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.